BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · 6 days ago
BioMarin Pharmaceutical Inc. $BMRN Stock: Assenagon Asset Management S.A. Lowers PositionDefense World · Oct 17, 2026
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value StockZacks Investment Research · Oct 13, 2026
Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)Defense World · Oct 12, 2026
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual MeetingPRNewsWire · Oct 9, 2026
FDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingZacks Investment Research · Oct 7, 2026BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $0.95 | $1.20 | Beat |
| May 4, 2026 | $0.78 | $0.76 | Miss |
| Feb 23, 2026 | $0.17 | -$0.24 | Miss |
| Oct 27, 2025 | -$0.15 | -$0.16 | Miss |
| Aug 4, 2025 | $0.86 | $1.23 | Beat |
| May 1, 2025 | $0.71 | $0.97 | Beat |